GlassScriptPhysician profile
Christopher J Brouillette
NPI 1891779013
$1,750.43
in general payments reported to CMS, 2019-2025
19 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.52 · 2021: $34.84 · 2022: $419 · 2023: $484 · 2024: $414 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217.44 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $212.15 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $206.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $206.02 | 2022-2023 | Ubrelvy |
| Abbott Laboratories | $169.85 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $159.48 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $135.25 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $101.19 | 2023-2024 | |
| Glaxosmithkline, LLC. | $76.40 | 2021-2024 | Arexvy, Shingrix |
| Pfizer INC. | $66.16 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.06 | 2022-2024 | Jardiance |
| Microtransponder, INC. | $23.65 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.42 | 2024 | |
| Dynavax Technologies Corporation | $18.25 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.25 | 2022 | |
| Bausch Health US, LLC | $14.66 | 2022 | |
| Currax Pharmaceuticals LLC | $11.52 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.10 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brouillette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.